A lipid based nanoformulation of sulforaphane and tamoxifen and method of preparation thereof

IN595439BActive Publication Date: 2026-07-15BHARTI MANGLA +4
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
IN202211015622
Authority / Receiving Office
IN · IN
Patent Type
Patents
Current Assignee / Owner
Filing Date
2022-03-21
Publication Date
2026-07-15
Estimated Expiration
2042-03-21

AI Technical Summary

Technical Problem

Current nanoformulations for managing breast cancer face challenges in enhancing oral bioavailability and reducing toxicity of tamoxifen, while also requiring effective delivery mechanisms for sulforaphane and tamoxifen to target breast cancer cells.

Method used

A lipid-based nanoformulation of sulforaphane and tamoxifen is developed, utilizing a nanocarrier system that enhances oral delivery, increases lymphatic uptake, and inhibits the p-glycoprotein efflux pump to improve the effectiveness of tamoxifen and reduce its toxicity, with surfactants like Tween80 and poloxamer188 used to stabilize the formulation and enhance permeation.

Benefits of technology

The nanoformulation significantly improves the delivery and effectiveness of tamoxifen to breast cancer cells, reducing offsite toxicity and overcoming multi-drug resistance, while maintaining stability and controlled release of both drugs.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The present invention relates to a lipid based nano formulation of sulforaphane and tamoxifen. In the present invention, a solid lipid used in the formulation of NLCs selected based on the capability of solid lipid to solubilize TAM. The proposed formulation comprises of 1-75 mg of tamoxifen, 1-15 mg of sulforaphane, 500-700 mg of precirol ATO 5 and / or Compritol, 125-250 mg of transcutol HP, 100-250 mg of poloxamer 188 and / or 407, and 100-250 mg of tween 80 or tween 20.
Need to check novelty before this filing date? Find Prior Art

Description

The present invention in general relates to a lipid based nanoformulation of sulforaphane and tamoxifen for managing breast cancer which precisely enhancing oral bioavailability, improving the effectiveness of breast cancer, and reducing tamoxifen (TAM) toxicity.BACKGROUND OF THE INVENTIONThe background information herein below relates to the present disclosure but is not necessarily prior art.Cancerisanon-contagious (90%) disease in which abnormal cells multiply uncontrollably and may invade surrounding tissues, though ancient people believed that it was a kind of crab. There are several cancer types, including sarcomas, melanoma, carcinoma, leukaemia, lymphoma, and CNS cancer. Major cause of cancer is gene (that regulate cell growth) mutation and the gene that cause cancer called oncogene (produced by the mutation in protooncogene). This genemutation divides and multiplies the cell in uncontrolled way and inactivates the tumor suppressor genes (TSG)or DNA repair genes.There are several cancer types, including sarcomas, melanoma, carcinoma, leukaemia, lymphoma, and CNS cancer. Sarcomas type cancer occurs in cartilage, blood vessels, and muscle, and bone, tissues either soft or connective of the body.Breast cells contains a hormone receptor, a protein that signal cells to grow eitherhealthyorcancerousthattriggeredbythetwohormonescalledestrogenorprogesterone. The excess amount of these hormones presents on receptor developshormone receptor positive breast cancer. The excess amount of HER2 protein on theirreceptor develops and reproduce HER2 BC (positive). Triple negative breast cancercells do not have estrogen, progesterone and HER2 receptor. This type of cancer isdifficultto treat. Although various attempts are made before, for providing variousnanoformulation for managing breast cancerand there exist many drawbacks in the existing.Therefore, there is need to introduce a novel and efficientnanoformulation for managing breast cancer. OBJECTIVE OF THE INVENTIONAn objective of the present invention is to attempt to overcome the problems of the prior art and providea lipid based nano formulation of sulforaphane and tamoxifen for managing breast cancer and a process of preparing the same.Further, the present invention provides a solution for enhancing oral bioavailability, improving the effectiveness, andreducing TAM toxicity.These and other objects and characteristics of the present invention will become apparent from the further disclosure to be made in the detailed description given below.SUMMARY OF THE INVENTIONAccordingly, the following invention providesa lipid based nanoformulation of sulforaphane and tamoxifen for managing breast cancer.The proposed invention enhances oral bioavailability, improves the effectiveness on breast cancer and reducing TAM toxicity.Herein a lipid based nanocarrier system is designed for the co delivery of TAM (a synthetic chemotherapeutic agent)and SFN (a natural chemo sensitizing agent) for their enhanced and efficient delivery to the breast cancer.This invention provides an enhanced oral delivery of TAMthrough intestine in the presence of SFN in lipid based nanocarrier thereby preventingthe first pass metabolism and increasing the lymphatic uptake of TAM; increasedsensitivityoftheestrogenreceptorsinthebreastcancercellsby SFN andsubsequently promote the binding of TAM to the estrogen receptors; reduced doseof TAM through synergistic effect when co delivered with SFN and subsequentlyreduce the offsite toxicity of TAM; inhibition of p-glycoprotein efflux pump andmulti drug resistance by SFN and ameliorate the cellular uptake of TAM by estrogenreceptorpositivebreastcancercells;surfactants(Tween80,poloxamer188, Tween 20)usedinthelipidbasednanocarrierasastabilizerenhancedthepermeationTAMbyinhibitingp-glycoprotein efflux pump presentin the intestinal milieu.BRIEF DESCRIPTION OF DRAWINGThis invention is described by way of example with reference to the following drawing where,Figure 1 of sheet 1 shows solubility study of TAM in solid lipids, liquid lipids, and surfactants. (A) Amount of solid lipid (g) required to solubilize 15 mg of TAM. (B) Solubility study of TAM in different liquid lipids.(C) Solubility study of TAM different in surfactants. Data represents mean± SD(n=3).Figure 2 of sheet 2 shows 3D response surface plots displaying the influence of different process variables on (A) particle size, (B) PDI and (C) % entrapment efficiency(TAM) and (D) % entrapment efficiency (sulforaphane) in TAM-sulforaphane-nano structured lipid carriers.Figure 3 of sheet 3 shows Particle size of lyophilized TAM-SFN-NLCs in the presence of mannitol concentration (A) 2.5%w / v and(B) 7.5% w / v.Figure 4 of sheet 3 shows Characterization of optimized TAM- sulforaphane-nano structured lipid carriers.(A) Particle size before lyophilization.(B) Particle size after lyophilization in the presence of 5% w / v mannitol.(C) Zetapotential. (D) Transmission electron microscopy image at 200 nm scale bar.(E) Scanning electron microscopy image at 200 nm scale bar.Figure 5 of sheet 4 shows DSC thermograms. (A) TAM; (B) Precirol ATO5; (C) Mannitol; (D)TAM-SFN-NLCs.Figure 6 of sheet 4 shows XRD profiles. (A) Precirol® ATO5; (B) TAM; (C) TAM and SFN intonanostructuredlipidcarriers; and(D) mannitol.Figure 7 of sheet 5 shows In vitro release profile of TAM (TAM) and sulforaphane (SFN) from TAM-suspension, SFN, TAM-SFN-suspension and TAM-SFN-nano structured lipid carriers. (A) pH 1.2; (B) pH 7.4. **p<0.01 compared with TAM-suspension and SFN and TAM-SFN-suspension.Figure 8 of sheet 5 shows Image represent the release kinetics models for optimized TAM-SFN-NLCs(A)TAM,(B) SFN.Figure 9 of sheet 5 shows % antioxidant activity of TAM, SFN, TAM+SFN, Blank NLCs, TAM-SFN-NLCs.In order that the way the above-cited and other advantages and objects of the invention are obtained, a more particular description of the invention briefly described above will be referred, which are illustrated in the appended drawing. Understanding that these drawing depict only typical embodiment of the invention and therefore not to be considered limiting on its scope, the invention will be described with additional specificity and details using the accompanying drawing.DETAILED DESCRIPTION OF THE INVENTIONThe present discloser relates, in general to a lipid based nanoformulation of sulforaphane and tamoxifen for managing breast cancer.In the present invention, a solid lipid used in the formulation of NLCs selected based on the capability of solid lipid to solubilize TAM. Accurately weighed quantity of TAM (1-75 mg) and solid lipid (200 mg) kept in glass vial and heated (5-10 ºC above the melting point of the solid lipid) with continuous stirring. Then, an excess amount of solid lipid added slowly until it formed a clear solution. The amount of solid lipid required to solubilize 5 mg TAM was noted. Since SFN was supplied in liquid form therefore, the solubility study of SFN was not performed.The solubility of TAM in various liquid lipids (oils) and 1% w / v surfactant solution was determined by the saturation solubility method as described previously. An excess amount of TAM was taken in glass vials containing a specific quantity (1 mL) of different liquid lipids and 1 mL surfactant solution (1% w / v). The glass vials were sealed and stirred continuously in a shaker incubator at 200 rpm for 24 h at room temperature. Then, drug mixtures were centrifuged at 3000 g for 30 min, and supernatants were collected, diluted with methanol, and quantified using the afore mentioned HPLC method.A binary mixture of solid lipid and liquid lipid used in the formulation of NLCs was selected based on the miscibility test method. Briefly, solid, and liquid lipid were mixed in different proportions (90:10, 80:20, 70:30 and 60:40) with continuous stirring at 400 rpm for 1 h at 80 ? to determine the miscibility of both lipids; The miscibility between these lipids was tested by smearing a lipid cooled sample mixture on a filter paper and examined visually to assess the presence of any oil droplets on the filter paper. A binary mixture that did not show any oil droplets on the filter paper was selected for the development of TAM-SFN-NLCs. Similarly, surfactant ratio was optimized by preparing placebo formulations with different ratios of surfactant and visually examining the consistency as well as phase separation in the formulations.The present disclosure relates to a formulation of TAM-SFN-NLCs, comprises of Tamoxifen,Sulforaphane, Precirol ATO 5 and / or Compritol as a solid lipid and Transcutol HP as a liquid lipid, poloxamer 188 and / or poloxamer 407and tween 80 and / or tween 20.In this embodiment to the present invention, accurately weighed quantity of solid lipid (500 mg) and liquid lipid (125 mg) were heated (5-10 ºC above the melting point of solid lipid) to form an oily phase in which the required amount of TAM (1-75 mg) and SFN (1-15 mg) were added. In a preferred embodiment to the present invention, accurately weighed quantity of solid lipid (500 mg) and liquid lipid (125 mg) were heated (5-10 ºC above the melting point of solid lipid) to form an oily phase in which the required amount of TAM (5 mg) and SFN (10 mg) were added. The aqueous surfactant phase was simultaneously prepared by dispersing poloxamer 188 and / or poloxamer 407 (100-250 mg) and tween 80 and / or (100-250 mg) (1:1 w / w) in milli-Q water and heated at the same temperature as of the oil phase. Then, surfactant phase was poured drop wise into oily phase under constant stirring at 900 rpm for 45 min using a magnetic stirrer. The resultant primary emulsion was then ultra-sonicated using a probe sonicator to obtain the dispersion, followed by cooling at room temperature where the lipid solidifies to form TAM-SFN-NLCs.TAM-suspension was prepared with 0.25% CMC-Na (Sodium Carboxymethyl Cellulose) under constant stirring for 15 min at 600 rpm. CMC-Na was used as a suspending agent to keep drug suspended in the dispersion medium.For lyophilization optimized TAM-SFN-NLCs were lyophilized to enhance the long-term stability of the formulation. This study utilized mannitol as a cryoprotectant and its concentration was optimized; 2.5%, 5% and 7.5% w / v to the total volume of the formulation. Samples containing different concentrations of cryoprotectants were frozen separately in lyophilization vials for 10 h, at -80 °C and the frozen samples were transferred to freeze-dryer for removal of water up to 48 h.The powdered cake of formulation was re-dispersed in milli-Q water to their original volume and gently shaken for 1 min. The effect of lyophilization was observed by measuring the particle size, PDI and redispersibility index (RDI) Embodiments and certain aspect explained in more detail with reference to the following experimentation details.Particle size and zeta potential measurement: Particle size and PDI were measured by Malvern Zetasizer instrument based on the dynamic light scattering (DLS) technique, which analyzes scattered light intensity produced by the movement of particles and generates mean particle size (z-average) and PDI. Zeta potential is a measure of the magnitude of the electrostatic or / attraction between particles and was measured using Malvern Zetasizer based on the electrophoretic mobility of the particles.TAM-SFN-NLCs were diluted in the ratio of 1:200 with milli-Q water and analyzed at a detection angle 90º at 25 ?. Each measurement was performed in triplicates (n=3).Determination of % Entrapment efficiency and drug loading: % EE and % drug loading of TAM-SFN-NLCs were determined by the separation of un encapsulated drug from the NLCs by centrifuging 2 mL of the drug-loaded TAM-SFN-NLCs at 55,000 g for 1 h at 4 ºC. The supernatant containing unentrapped drug was removed and analyzed by HPLC method.Surface morphology: Surface morphological observation of TAM-SFN-NLCs was performed viatransmission electron microscopy (TEM) and scanning electron microscopy (SEM). For TEM measurement, a drop of diluted sample was mounted on 200 carbon-coated copper mesh grid and negatively stained with a solution of 2% (w / v) phosphotungstic acid to improve the contrast. After that, the samples were kept for air-drying at room temperature and images were recorded by observing under the electron microscope. Similarly, for SEM measurement, a drop of diluted sample was mounted on the glass slide and dried, followed by sputter coating with gold for 30 min and examined under SEM. Photomicrographs were taken at the accelerated voltage of 200kVand a chamber pressure of 0.6 mmHg.Differential scanning calorimetry: Differential scanning calorimetry (DSC) was used to measure the state of the drug (crystallinity or amorphousstate) in the TAM-SFN NLCs matrix utilizing Pyris6DSC (Perkin Elmer, Pyris series). Approximately 2 to 3 mg of sample was loaded in an aluminum pan, whereas an empty pan was used as a reference. The sample was then allowed to run in the temperature range of 40 °C to 250 °C at 10 ºC / min under nitrogen gas flow at 10mL / min.X-ray diffraction study: X-ray diffracto meter was used to monitor the changes in the crystalline structure of the developed formulation. For this, the samples were scanned at a speed of 2º / min (2?) in the range 4º to 50º with 100 mA current at0.02°level. The XRD spectra were recorded and evaluated.In vitro drug release study:The drug release study of TAM and SFN from TAM-Susp, SFN, TAM-SFN-Susp and TAM-SFN-NLCs was conducted using dialysis bag method. In this study, 0.1N HCL pH 1.2 and phosphate buffer saline (PBS) pH 7.4 were taken as the dissolution medium. Before the experiment, the dialysis bag (molecular weight cutoff 10 kDa) was soaked overnight in the dissolution medium. The sample was placed in the dialysis bag before being immersed into 50 mL dissolution media with 0.5% v / v of Tween80, stirred at 100 rpm at 37±0.5ºC for 2h at whereas for 24h at pH 7.4. After specific time intervals, 500 µL of the sample was withdrawn through a side tube and immediately replaced with an equal amount of fresh dissolution medium. Thereafter, the samples were filtered and analyzed by above- mentioned HPLC method.Release kinetic modeling was performed by putting the cumulative release data (pH7.4) into zero-order, first-order, Hixson-Crowell, Higuchi, and Korsmeyer- Peppasrelease kinetic model, and the model with the highest value of correlation coefficient(r2) was taken as the best fit model.Stability study: The optimized lyophilized TAM-SFN NLCs were subjected to stability study concerning temperature conditions according to the ICH guidelines Q1AR2. Lyophilized samples were kept at two different temperature conditions: 4? and 25? / 60% RH. At various time intervals (1, 2, 3 months), samples were withdrawn and reconstituted with milli-Q water and analyzed for particle size, PDI, and % EE.Antioxidant activity:Antioxidant activity was performed by DPPH experiment as reported previous literature of all test samples i.e., free TAM, free SFN, TAM + SFN, blank NLCs andTAM-SFN-NLCs. Stock solution of all test samples were prepared in methanol (1000mg / mL). Prepared 0.3 mM DPPH solution using methanol. Then took 100µL from the all-test samples and equally dissolved with DPPH solution. This mixture was incubated at room temperature for 30 minutes in dark and absorbance (Abs) was taken at 517 in UV spectrophotometer (microplate). Then calculate the % scavenging activity by using following formula and Trolox was considered as control for DPPH experiment.% Scavenging activity=Abscontrol -Abssample / Abscontrol×100Results of experimentation: Selecting solid lipid: The solubility study was performed for TAM only since SFN was provided in liquid form. The solubility of TAM was tested in different solid lipids such as Precirol ATO5, Compritol 888 ATO, Apifil, Gelucire 48 / 16, Gelucire 50 / 13, Tefose 63, Stearic acid and Geleol mono and diglycerides NF. Based on results, TAM exhibited low solubility in Apifil, Gelucire 48 / 16, Gelucire 50 / 13, Tefose63, Stearicacid and Geleol mono and diglycerides NF whereas relatively higher solubility in Precirol ATO 5 and Compritol 888 ATO as shown in figure 1 (A). The study data revealed that higher quantities (>2000mg) of Apifil, Gelucire 48 / 16, Gelucire 50 / 13, Tefose 63, Stearic acid and Geleol mono and diglycerides NF were required to solubilize TAM. However, a lesser amount of Precirol ATO 5 and Compritol 888 ATO were required to solubilize 5 mg of TAM (figure 1 (A). The quantity of Precirol ATO 5 and Compritol888 ATO required to solubilize 5 mg of TAM was found to be 0.87± 0.12g and 1.32 ±0.83 g, respectively.Selection liquid lipid and surfactant: The solubility data of TAM in various synthetic liquid lipid (Labrafil M 1944 CS, Capmul MCM, Transcutol HP) and natural lipid (Canola oil, Corn oil, Olive oil) is shown in figure 1 (B). In our study, Transcutol HP (diethylene glycol monoethylether) demonstrated the best solubilizing effect forTAM (75±0.32mg / mL) in comparison to other liquid lipids, and hence, selected for the formulation of TAM-SFN-NLCs. Similarly, the solubility data of TAM in different surfactants are presented in figure 1 (C). The study data revealed that Tween 80 and Poloxamer 188 showed highest solubility for TAM as compared to Cremophor EL and Tween 20.Therefore, Poloxamer 188 and Tween 80 were chosen as the surfactants for the formulation of TAM-SFN-NLCs.Binary mixture of solid lipid and liquid lipid selection: The binary mixture (solid and liquid lipid) that was utterly miscible with each other was selected for the preparation of NLCs. By the obtained solubility data, Precirol ATO 5 (solid lipid) and Transcutol HP (liquid lipid) were mixed to form a binarymixture. As per the visual observation of smear test of the binary mixture sample, thedroplets of Transcutol HP were not observed on the filter paper by adding up to 20% (w / w) of Transcutol HP to the selected solid lipid. Above this concentration of Transcutol HP, some of the droplets were observed on the filter paper. Therefore, the results suggested that binary mixture with ratio 90:10, 70:30, 60:40 was not likely to be miscible with the solid lipid. As a result, binary mixture consisting of 80% Precirol ATO 5 and 20% (w / w) of Transcutol HP was selected as a suitable combination for the preparation of TAM-SFN-NLCs.Optimization of TAM-SFN-NLCs: To carry out the optimization of TAM-SFN-NLCs, solid lipid concentration (X1), sonication time (X2) and surfactant concentration (X3) were selected as the independent variables. From table 1, it was observed that dependent variables, namely particle size (Y1) ranged from 95 to 188 nm, PDI (Y2) ranged from 0.1-0.33 and % EE of TAM (Y3) and SFN (Y4) were found in the range of 60-83% and 61-82%, respectively. The predicted responses of 17 runs were fitted into different models; first order, second order & quadratic model, whereas dependent variables were fitted to quadratic model with coefficient of correlation less than1.Table 1: Different trial runs generated in box-behnken design and observed responses for TAM-SFN-NLCs.Run Solid lipid (mg) Sonication time (min) Surfactant (mg) Particle size(nm) PDI % EE (TAM) % EE (SFN)1 500 45 200 121.9 0.242 76.7 74.52 500 60 100 175.8 0.312 75.1 74.73 300 60 200 119.3 0.235 60.16 61.54 300 45 100 143.2 0.202 70.3 69.35 500 45 200 121.8 0.233 75.6 73.36 500 45 200 123.1 0.228 76.1 75.37 300 30 200 131.2 0.186 71.2 73.58 500 30 300 144.6 0.245 77.4 75.19 300 45 300 95.3 0.205 64.3 65.310 700 30 200 188.8 0.221 79.2 76.411 500 60 300 133.8 0.255 71.3 69.812 700 45 100 188.8 0.258 82.9 79.713 500 45 200 122.2 0.227 75.3 74.114 700 60 200 180.8 0.338 78.7 81.715 700 45 300 163.8 0.255 80.2 79.316 500 30 100 181.8 0.175 81.7 74.717 500 45 200 121.3 0.235 75.9 74.3The three-dimensional (3D) response surface graphs were obtained and presented in Figure 2. The adequacy of the fitted model was examined by analysis of variance (ANOVA).The data were fitted to the second- Order polynomial equation (Equations 2, 3& 4) where it was observed that the relationship between the independent variables (X1, X2, X3) and the dependent variables (Y1, Y2, Y3, Y4) is not alwayslinear. A positive value in polynomial equation indicates that the dependent variables were directly related to independent variables. In contrast, the negative value represents an inverse relationship between the independent variables and dependent variables.Effect of independent variables on particle size (Y1): The particle size of TAM-SFN-NLCs was observed to be in the range of 95-188 nm as shown in table 1.The effect of solid lipid concentration (X1), sonication time(X2) and surfactant concentration (X3) on particle size (Y1) is shown in equation 2.The r2 value was found to be 0.9991, signifying a good fit of the model (p value=0.05).Particle size (Y1) = 121.88 + 29.15X1-4.59X2-19.01X3+ 0.9750X1X2+ 5.72X1X3-1.2X2X3+10.96X2+22.19X22+14.94X2(2).In line with equation 2, it was ascertained that particle size has a positive relationship with the concentration of solid lipid (X1) and an inverse relationship with the sonication time(X2) and surfactant concentration (X3) as shown in figure 2(A).Effect of independent variables on PDI(Y2): PDI plays a significant role in defining the stability of the prepared NLCs. The PDI value of prepared NLCs was found to be in the range of 0.1 to 0.33, as summarized in table 1. A lower PDI value suggests that the particles are homogenous with narrowsize distribution. The influence of the independent variables (X1, X2, X3) on PDI ofTAM-SFN-NLCs is represented in equation 3. The r2 value was found to be 0.9909, respectively and found to be statistically significant (p value=0.05)PDI (Y2) = 0.231 + 0.0304X1+ 0.0392X2+ 0.0016X3+0.0173X1X2– 0.0015X1X3-0.0317X2X3-0.0015 X2+ 0.01593 X22+0.0005 X32 (3)PDI was observed to have a positive relationship with all three independent variables, namely, concentration of solid lipid (X1), sonication time (X2) and concentration of surfactant(X3), as shown in Figure 2 (B) and equation 3.Effect of independent variables on % EE (Y3 and Y4):% EE of TAM (Y3) and SFN (Y4) in TAM-SFN-NLCs were found to be in the range of 60-85% as summarized in table 1. Equations 4 & 5 represent the impact of theindependent variables (X1, X2, X3) on the % EE of TAM (Y3) and SFN (Y4) in TAM-SFN NLCs. The r2 value for Y3 and Y4 was found to be 0.9968 & 0.9922, respectively. Results depict the excellent fit of the model (p value =0.05). % EE of TAM (Y3) = 75.5 + 6.95 X1-2.99X2-2.14X3+ 2.64X1X2+ 0.8250X1X3+0.25X2X3-2.58 X12– 0.6050X22+1.36X32(4) % EE of SFN (Y4) = 74.06 + 5.89X1-1.64X2 - 1.13X3+ 4.42X1X2+ 0.9000X1X3-1.35X2X3-0.34A X12-0.5425 X22-0.3175 X2(5) From the polynomial equations 4, it was interpreted that the solid lipid concentration(X1) showed a positive correlation with % EE of both the drugs. Similar observation was concluded from Figure 2 (C) & (D).Lyophilization of TAM-SFN-NLCs: In this study, the concentration of mannitol required to produce stable NLCs was optimized after lyophilization by maintaining the proper particle size, PDI and % EE of the drug. At first, NLCs were lyophilized in the presence of 2.5% w / v mannitol. After reconstituting with original volume of milli-Q water, the particle size was observed to be 433.8±8.62 with PDI0.59±0.03 (figure 3), whereas there dispersibility index was found to be more than 300 (table 2). At this concentration of mannitol higher reconstitution time as well as slightly higher residual moisture content was observed (table 2). These results further indicated that this concentration of lyoprotectant used for lyophilization of NLCs was not sufficient to protect the physical characteristics of lyophilized formulation.On the other hand, when the concentration of mannitol was increased to 5% w / v, the particle size and PDI of the lyophilized NLCs were close to their initial value (before lyophilization) Figure 4 (A) & (B) and table 2. These results revealed that optimum lyoprotectant concentration is necessary to maintain the physical characteristics as well as the structural integrity of the lyophilized NLCs. Moreover, 5% w / v mannitol showed minimum reconstitution time and lowest residual moisture content along with the elegant fluffy cake of the lyophilized product (table 2). Then again, 7.5% w / v mannitol concentration could not protect the particle size and PDI (328.6 ± 7.98 and 0.418 ± 0.06) of the lyophilized NLCs. Furthermore, it showed higher reconstitution time as well as higher residual moisture content (table 2), suggesting that a higher concentration of mannitol might cause osmotic instability in the lyophilized NLCs. Thus, based on the above-elucidated results, 5% w / v mannitol was selected as the optimum lyoprotectant concentration for the lyophilization of TAM-SFN-NLCs as it would further enhance the long-term stability of the lyophilized nano particles.Table 2: Lyophilization of TAM-SFN-NLCs in the presence of mannitol. Data represents mean ± SD (n=3). TAM-SFN- 121.9 ± 0.24 Liquid ----- ----- ----NLCs beforeLyophilization 6.42 ±0.05 state 2.5% w / v 433.8 ± 0.59 Sticky 2.92 ± 82 357.8Mannitol 8.62 ±0.03 cake 0.20 5% w / v 129.6 ± 0.25 Intact 1.51 ± 50 107.3Mannitol 5.42 ±0.04 fluffycake 0.15 7.5% w / v M 328.6 ± 0.41 Collapsed 2.62 ± 75 271.0mannitol 7.98 ±0.06 cake 0.17 In vitro characterizationParticle size, PDI and zeta potential measurement:Particle size and PDI of the optimized TAM-SFN-NLCs was found to be 121.9 ± 6.42nm and 0.242 ± 0.05, respectively (Figure 4A), indicating that nano formulation was in the nano metric range with a homogenous population.The zeta potential of optimized TAM-SFN-NLCs was found to be -21.2 ± 2.91 mV(Figure 4C), suggesting the preparation of a stabilized nano formulation.Determination of % entrapment efficiency and drug loading: % EE of TAM and SFN in TAM-SFN-NLCs was found to be 76.7±3.34% and 74.5 ±2.92%, respectively, indicating that optimized nano formulation showed higher encapsulation of both the drugs at the optimum ratio of solid as well as liquid lipid. The actual and theoretical drug of TAM was found to be 0.607 ± 0.054% and 0.79%,respectively and for SFN it was found to be1.74±0.23%and 2.34%,respectively.Surface morphology: The morphological observation of optimized TAM-SFN-NLCs under TEM discovered that the particles were spherical, having a uniform and nano metric size (Figure 4D). Moreover, the particle size was in corroboration with the DLS measurement. Similarly, SEM image of optimized TAM-SFN-NLCs showed spherical particles within the nano metric range (Figure 4E). Consequently, these observations revealed that a perfect spherical nano matrix system was developed.Differential scanning calorimetry analysis: The DSC thermograms of TAM, Precirol ATO 5, TAM-SFN-NLCs and mannitol are shown in figure 5. Since SFN was available in liquid form, hence DSC of SFN was not performed. Further, the DSC curve of TAM and mannitol showed an endothermic peak at around 148.7? and172.1?, respectively, suggesting the crystalline state of TAM and mannitol. Precirol ATO 5 displayed a sharp endothermic peak at around 65.0? with as light and well-defined shoulder peak at 53.7 ? corresponding to the melting point of the a-polymorphic form of the lipid. Thermogram of TAM-SFN-NLCs displayed three endothermic peaks at 46.7 ?, 60.8 ? and 169.9 ? with the former two peaks of Precirol ATO 5 and later for mannitol. The melting point of lipid dropped from 65? to 60?, which could be due to the increased lattice defects caused by the addition of liquid lipid. Moreover, it was observed that the endothermic peak of drug at 148.7 ? disappeared in TAM-SFN-NLCs.X-ray diffraction study:XRD studies were conducted to investigate changes in the crystalline structure of thelyophilized NLCs. The X-ray diffractograms of Precirol ATO 5, TAM, TAM-SFN-NLCs and mannitol are displayed in figure 6. The diffractogram of TAM exhibited an intense and distinct sharp peak at 2? values 2.98°, 11.72°,13.92°, 17.80°, 19.08° and several medium-intensity peaks at 2? values 9.52°,19.16°,and 16.36°, indicating to the perfect crystalline nature of TAM. The diffractogram of Precirol ATO 5 showed a very high intensity peak at 2? equal to 19.34°, 21.04 and 23.94° suggesting the waxy nature of lipid materials. Whereas, in TAM-SFN-NLCs three diffraction peaks of Precirol ATO5 were observed at 2? values 19.02°, 20.36° and 21.12° at low intensity, suggesting that the incorporation of liquid lipid into the solid lipid caused imperfections in the crystalline nature of the solid lipid.Invitro drug release study: Invitro release of TAM and SFN from TAM-Susp, SFN, combined suspension (TAM-SFN-Susp) and TAM-SFN-NLCs in 0.1 NHCL (pH1.2) and PBS(pH7.4) is shown in figure 7 (A) & (B), respectively. In the acidic medium (0.1 N HCL, pH1.2), TAM-Susp and SFN and TAM-SFN-Susp released 25-30% of TAM and SFN within 2 h. In contrast, TAM-SFN-NLCs released only 4-7% of TAM and SFN within 2 h, indicating to the protective nature of lipid-based nano formulation towards the acidic medium i.e., pH of the stomach. This would further help in the protection of drug from premature degradation in the stomach.In vitro release at pH 7.4, demonstrated that release of TAM and SFN from TAM-SFN-NLCs was nearly about 75-78% after 24 h whereas release from their individual and combined suspensions were about 27-30% after 24 h.Further, to analyze the drug release mechanism from the lipid-based nano formulation, the release pattern was fitted into several release kinetic models (figure 8). From this release kinetic fit model, it was observed that Higuchi diffusion model was the most appropriately fitted model with highest r2 value 0.9925 and 0.9867 for TAM and SFN, respectively, as compared to other models (table 3).Table 3: Equation with correlation of coefficient (r2) of release kinetic model of TAM and SFN from TAM-SFN-NLCs.Stability study: Stability study of the optimized lyophilized TAM-SFN-NLCs was performed concerning particle size, PDI, and % EE for 3 months at 4 ? and 25? / 60% RH. The particle size and PDI measured after 3 months were within the acceptable range, below 200nm (table 4). We observed slight changes in the % EE after time might be due to aging or slight expulsion of the drug from the lipid matrix (table 4). However, the changes were not significantly different when compared with the initial value. This indicated that NLCs could be stored for an extended time in a dry state as well as easily reconstituted and used whenever required.Table 4: Stability study of optimized lyophilized TAM-SFN-NLCs at different temperature conditions. Values are expressed as mean± SD (n=3).Storage Time Particle size PDI % Entrapment efficiencyconditions (month) (nm) TAM SFNInitial 0 129.9 ± 6.42 0.242 ± 0.05 76.7 ± 3.34 74.5 ± 2.924 ºC 1 133.4 ± 7.22 0.246 ± 0.03 74.6 ± 3.05 73.1 ± 2.65 2 141.6 ± 5.99 0.251 ± 0.02 74.1 ± 2.55 72.9 ± 2.41 3 149.2 ± 7.21 0.258 ± 0.03 72.3 ± 2.76 71.2 ± 3.0625 ºC 1 139.3 ± 4.99 0.244 ± 0.02 74.7 ± 4.12 72.3 ± 3.65 2 144.8 ± 8.98 0.253 ± 0.03 72.5 ± 2.34 71.9 ± 1.99 3 151.6 ± 5.44 0.256 ± 0.02 72.8 ± 2.48 71.2 ± 2.90Antioxidant activity: Figure 9, indicates the % scavenging (inhibition) activity of all tests, i.e., free TAM, free SFN, Tam & SFN combination, blank-NLCs, and TAM-SFN-NLCs. No antioxidant activity against DPPH is present in free TAM and blank NLCs. SFN, on the other hand, demonstrated high antioxidant activity either in combination with free TAM or in NLCS. SFN, on the other hand, demonstrated high antioxidant activity either in combination with free TAM or in NLCs. Our aim is to reduce the oxidative stress of TAM-SFN-NLCs generated during TAM therapy. Therefore, we carried out the antioxidant activity of TAM-SFN-NLCs to verify the functional stability of SFN in NLCs.Conclusively selecting suitable solid lipid, liquid lipid and other excipients is an essential factor to produce poorly soluble drug loaded NLCs. More essential in drug solubilization is the chemical nature of lipids. Precirol ATO 5 consists of a mixture of relatively short-chain length acyl glycerols of distearate, tripalmitin, and tristearin that provide more imperfection, offering space for higher drug loading and % EE. Therefore, in this study, Precirol ATO 5 was chosen as the most appropriate solid lipid for the development of TAM-SFN-NLCs for oral delivery. Besides solid lipid, it is equally important to select a suitable liquid lipid in NLCs to produce stable nano formulation. The solubility of TAM in synthetic oils was found to be higher as compared to the natural oils that could be due to surfactant properties of synthetic oils. Besides, synthetic oils tend to have a better solubilizing effect at high temperatures, low viscosity, and prolonged shelf-life.Moreover, Transcutol HP has been classified as a polar protic solubilizer with a negative log P, which indicating affinity and strong miscibility with hydrophobic groups present in the drug. Therefore, Transcutol HP was selected as a liquid lipid. It was reported that a combination of surfactant has shown better stability and efficiency in producing nano particles. Consequently, combination of poloxamer and tween 80 was selected in equal proportion (1:1 w / w) based on its ability to produce a clearer and stable emulsion.TAM-SFN-NLCs were produced by ultra-sonication method. Independent factors i.e.solid lipid (X1), sonication time (X2) and surfactant (X3) has been reported to play acritical role in the fabrication and stabilization of NLCs. As the concentration of the solid lipid in the formulation was increased, particle size increased as well. This could be due to the distribution of ultra-sonication energy was not sufficient to reduce the particle size in concentrated formulation. The second factor; sonication time (X2) showed a negative effect on particle size as sonication time increased, particle size has been reduced. This could be due to the sonic energy that prevents particle aggregation.Similarly, surfactant concentration (X3) also displayed an inverse relation with particle size (Y1). This could be due to the surfactant’s emulsifying efficiency ability and steric stabilizing effect. In addition, surfactant molecules stabilize the formulation by forming a thick protective layer over the particle droplets and decrease the surface tension between the lipid and aqueous phase of NLCs, thus preventing particle agglomeration. It has been observed that PDI increased significantly byrising thesolid lipid concentration. Sonication time (X2) also showed a positive impact on thePDI that maybe attribute to the higher sonic energy that rapidly separates particles and few of them get aggregated immediately.Similarly, it was found surfactant concentration (X3) had a positive relation with PDI; however, the impact was significantly less. This suggested that lipid concentration in the formulation substantially provides more space for drug particles aggregation and prevent the expulsion of drug to the external phase. Moreover, the hydrophobic nature of Precirol ATO 5 provides higher entrapment of both drugs i.e., TAM and SFN. On the other hand, sonication time (X2) and surfactant concentration (X3) showed a negative effect on % EE of TAM (Y3) and SFN(Y4).The decrease in % EE of bothdrugs in the TAM-SFN-NLCs with respect to sonication time (X2) could be since highsonic energy breaks the particles and facilitates the release of drug to the external surface.Similarly, surfactant concentration showed an inverse relationship with % EE. This might be due to the partitioning of drug from the internal lipid phase to the external surfactant phase. Based on these data, the optimized NLCs consisting of 500 mg solid lipid, 200 mg surfactant concentration with sonication time of 45 sec and were selected for further experimentation.Furthermore, particle size less than 200 nm are readily acceptable in the nano medicine and believed to cross the cell membrane easily as well as show stupendous advantages at the target site. PDI is characterized by uniformity in the dispersion and ranges from 0 to 1. Lower PDI implies a homogeneous distribution of size, while PDI greater than 0.5 indicates a wide distribution and poly disperse of size. A negative value of zeta potential may be due to the presence of glycerides in Precirol ATO 5 that ionized fatty acids.Lyophilization, also known as freeze-drying technique, has been widely used to enhance the physical and chemical stability of various drugs, bio pharmaceutical products and nano medicines in a dry state for a long period of time. In this process, liquid the formulation is frozen and removed via sublimation. Thus, mannitol was selected as a lyoprotectant and bulking agent in this study that was used to enhance the long-term stability of TAM-SFN-NLCs by lyophilization.DSC and XRD studies suggest that the drug was either molecularly dispersed orwholly solubilized in the lipid matrix and converted from a crystalline state to an amorphous state due to the presence of lipid matrix. This also indicates that the drugs were encapsulated entirely inside the lipid matrix.Further, an in vitro release finding indicates that TAM-SFN-NLCs showed biphasic release behavior, where the first phase lasted up to 4 h for both the drugs with a relatively rapid release, which might be due to the drug particles enriched around the surfactant layer. From the results, TAM-SFN-NLCs enhanced the release rate of both drugs and showed sustained-release behavior. Also, the different model indicates that the release of drug from NLCs usually occurs by diffusion mechanism. It was further confirmed that anti-oxidant activity of TAM-SFN-NLCs was entirely contributed by SFN and not by TAM or blank NLCs (negligible scavenging activity of free TAM and blank NLCs).The formulations are suitable for oral, buccal, sublingual, topical or intravenous / intramuscular administration. Preferably, the formulations are administered orally.Best method of performing the invention: a) Mixing 500-700 mg of Precirol ATO 5 and / or Compritol as a solid lipid (500-700 mg) with 125-250 mg of Transcutol HP as liquid lipid (125-250 mg) and heating up to 5-10 ºC above the melting point of solid lipid to form an oily phase; b) Adding 1-75 mg of tamoxifen and 1-15 mg of sulforaphane in a prepared oily phase;c) Preparing an aqueous surfactant phase by dispersing 100-250 mg of poloxamer 188 and / or poloxamer 407 and 100-250 mg of tween 80 and / or tween 20 in milli-Q water and heating at the same temperature as of the oil phase; d) Pouring the prepared surfactant phase drop wise into the oily phase under constant stirring at 900 rpm for 45 min using a magnetic stirrer; ande) Ultra-sonicating the resultant primary emulsion using a probe sonicator to obtain the dispersion and followed by cooling at room temperature where the lipid solidifies to form TAM-SFN-NLCs;

Claims

We claim:

1. A stable lipid based nano formulation of sulforaphane and tamoxifen, comprises of;1-75 mg of tamoxifen,1-15 mg of sulforaphane,500-700 mg of precirol ATO 5 and / or Compritol,125-250 mg of transcutol HP, 100-250 mg of poloxamer 188 and / or 407; and 100-250 mg of tween 80 or tween 20.

2. A method of preparation of stable lipid based nanoformulation of sulforaphane and tamoxifen, consisting of following steps;a) Mixing 500-700 mg of Precirol ATO 5 and / or Compritol as a solid lipid (500-700 mg) with 125-250 mg of Transcutol HP as liquid lipid (125-250 mg) and heating up to 5-10 ºC above the melting point of solid lipid to form an oily phase; b) Adding 1-75 mg of tamoxifen and 1-15 mg of sulforaphane in a prepared oily phase;c) Preparing an aqueous surfactant phase by dispersing 100-250 mg of poloxamer 188 and / or 407 and 100-250 mg of tween 80 or tween 20 in milli-Q water and heating at the same temperature as of the oil phase; d) Pouring the prepared surfactant phase drop wise into the oily phase under constant stirring at 900 rpm for 45 min using a magnetic stirrer; ande) Ultra-sonicating the resultant primary emulsion using a probe sonicator to obtain the dispersion and followed by cooling at room temperature where the lipid solidifies to form TAM-SFN-NLCs.

3. The method of preparation of lipid based nanoformulation of sulforaphane and tamoxifen as claimed in claim 2 wherein tamoxifen - suspension prepared with 0.25% Sodium Carboxymethyl Cellulose (CMC-Na) under constant stirring for 15 min at 600 rpm.

4. A stable lipid based nano formulation as claimed in claim 1 as and when used for managing breast cancer in suitable dosage form.